Survodutide
Survodutide (BI 456906)
Survodutide (BI 456906) is an investigational dual glucagon/GLP-1 receptor agonist peptide developed by Boehringer Ingelheim, currently in Phase 2/3 clinical trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). It is a fatty acid-modified peptide designed for once-weekly subcutaneous administration, combining glucagon receptor activation to increase energy expenditure with GLP-1 receptor activation to reduce appetite and improve glycemic control.
Mechanism of Action
Survodutide acts as a co-agonist at both glucagon receptors (GCGR) and glucagon-like peptide-1 receptors (GLP-1R), simultaneously activating two complementary metabolic pathways. GLP-1R activation suppresses appetite via central and peripheral mechanisms, slows gastric emptying, and enhances glucose-dependent insulin secretion, while GCGR activation increases hepatic glucose output, promotes lipolysis, raises basal metabolic rate, and drives fat oxidation in the liver—making it particularly relevant for hepatic steatosis. This dual agonism produces additive or synergistic weight loss and metabolic effects compared to GLP-1 mono-agonism alone.
Evidence by Health Goal(18 goals)
Dosing Protocols
Same day each week, subcutaneous injection into abdomen, thigh, or upper arm
Cycle: Dose escalation over 12–24 weeks; starting dose typically 0.3mg weekly, titrating up through 0.9mg, 1.8mg, 3.6mg, and 6.0mg based on tolerability
Dose escalation schedule is critical to minimize gastrointestinal side effects. Clinical trials used structured escalation protocols over 16–24 weeks. Currently not approved; only available in clinical trial settings or as a research peptide.
Safety & Side Effects
Survodutide is an investigational compound not yet approved by the FDA or EMA, meaning its full long-term safety profile remains under evaluation; use outside of clinical trials carries meaningful unknown risks. Known safety signals from Phase 2 data include GI tolerability challenges during titration and a dose-dependent increase in heart rate; caution is warranted in individuals with cardiovascular disease, a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2.
Possible Side Effects
- !Nausea (most common, particularly during dose escalation phases)
- !Vomiting, often associated with rapid dose titration
- !Diarrhea or loose stools
- !Decreased appetite and early satiety
- !Constipation (can alternate with diarrhea)
- !Injection site reactions including redness, swelling, or mild pain
- !Hypoglycemia risk when co-administered with insulin secretagogues
- !Elevated heart rate (tachycardia, attributed to glucagon receptor component)
Interactions
- -Insulin and insulin secretagogues (e.g., sulfonylureas): additive hypoglycemic effect requiring dose adjustment or monitoring
- -Oral medications with narrow therapeutic index: glucagon receptor activation and slowed gastric emptying can alter absorption kinetics of drugs like warfarin or levothyroxine
- -Antihypertensive agents: GLP-1-mediated blood pressure reduction may be additive, increasing risk of hypotension
- -Other GLP-1 receptor agonists (e.g., semaglutide, liraglutide): concurrent use is contraindicated due to overlapping receptor mechanisms and compounded GI toxicity
- -Beta-blockers: may blunt glucagon-mediated glycogenolysis and mask hypoglycemia symptoms, complicating safety monitoring
Cost & Where to Buy
Survodutide is not commercially available; costs reflect research-grade peptide vendor pricing, which varies substantially by purity, source, and batch size. Clinical trial participants receive the compound at no cost. Research peptide sourcing carries significant quality and legal risk as the compound is investigational and unregulated outside of trials.
Search on Amazon